-- Jarden在周四的一份報告中指出，Tabcorp Holdings (ASX:TAH) 可能面臨新的監管執法調查帶來的補救成本，且可能被認定為慣犯，但這兩項因素都不足以解釋該公司股價如此大幅下跌的原因。 澳洲交易報告和分析中心 (AUSTRAC) 正在調查該公司在反洗錢和反恐融資方面的合規情況，並對其識別和降低風險的能力表示擔憂。 Jarden指出，由於監管機構的揭露表明所有結果都在考慮範圍內，因此無法確定是否會受到罰款。而過去的案例表明，如果監管機構對合作情況感到滿意，則有可能免除罰款。 這家股票研究公司表示，AUSTRAC先前對博彩業的罰款金額從零到4.5億澳元不等，並補充說，他們認為這起事件對Tabcorp的營收影響有限。 調查披露後，該公司股價大幅下跌。 Jarden表示，以目前的股價來看，「該股似乎反映的成本影響遠超過既有先例所支持的範圍」。 Jarden維持對Tabcorp的「增持」評級，目標價為1.05澳元。 Jarden表示，如果澳洲交易報告和分析中心（Austrac）提起民事處罰訴訟或Tabcorp提列與此案相關的準備金，Jarden將重新評估該評級。 該公司股價在上週五的交易中下跌了13%。
Related Articles
Asia
Apollo Micro Systems Clinches Orders Worth INR510 Million; Shares Up 4%
Defense manufacturer Apollo Micro Systems (NSE:APOLLO, BOM:540879) has secured new orders worth a total of 510.3 million Indian rupees, according to a Friday filing to the Indian stock exchanges.Of the total, orders of 174.8 million rupees from the Ministry of Defence, Government of India, contracts of 95.3 million rupees from public sector defense undertakings, and orders worth 240.2 million rupees from private companies.The company's shares were up nearly 4% in recent trade.
$BOM:540879$NSE:APOLLO
Asia
PKU HealthCare Gets Nod for Tofacitinib Citrate's Marketing
PKU HealthCare (SHE:000788) obtained approval from China's National Medical Products Administration for the marketing of Tofacitinib Citrate, according to a Shenzhen bourse filing on Friday.The drug is a potent Janus kinase (JAK) inhibitor, primarily used for patients suffering from chronic autoimmune conditions, including ankylosing spondylitis, rheumatoid arthritis and psoriatic arthritis.The healthcare company's share rose 1% during the afternoon trade.
$SHE:000788
Asia
Toyota Expects Lower Fiscal 2027 Profit Amid Tariff, Cost Pressures
Toyota Motor (TYO:7203) forecasts weaker profit for fiscal 2027 as rising material and energy costs linked to Middle East tensions are expected to weigh on earnings, according to a Friday filing on the Tokyo Stock Exchange.The automaker expects net income attributable to shareholders to decline 22% to 3 trillion yen in the year ending March 2027, with basic earnings per share projected at 251.25 yen. Revenue is expected to rise slightly to 51 trillion yen.For the fiscal year ended March 2026, Toyota reported net profit attributable to shareholders of 3.848 trillion yen, down 19% from a year earlier, while revenue rose 5.5% to 50.7 trillion yen. Earnings per share fell to 295.25 yen from 359.56 yen a year earlier.The company raised its annual dividend to 95 yen per share from 90 yen and forecast a payout of 100 yen for fiscal 2027.
$TYO:7203